satralizumab
Selected indexed studies
- Satralizumab. (, 2012) [PMID:38985925]
- Satralizumab: First Approval. (Drugs, 2020) [PMID:32797372]
- Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. (N Engl J Med, 2019) [PMID:31774956]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Satralizumab. (2012) pubmed
- Satralizumab: First Approval. (2020) pubmed
- Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. (2019) pubmed
- Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. (2020) pubmed
- Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar. (2022) pubmed
- Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder. (2023) pubmed
- Long-term Efficacy of Satralizumab in AQP4-IgG-Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar. (2023) pubmed
- Satralizumab. (2006) pubmed
- Satralizumab for neuromyelitis optica spectrum disorder. (2022) pubmed
- Satralizumab-mwge. (2021) pubmed